• LAST PRICE
    0.3399
  • TODAY'S CHANGE (%)
    Trending Down-0.0051 (-1.4783%)
  • Bid / Lots
    0.3310/ 253
  • Ask / Lots
    0.3400/ 250
  • Open / Previous Close
    0.3520 / 0.3450
  • Day Range
    Low 0.3251
    High 0.3685
  • 52 Week Range
    Low 0.2400
    High 1.3100
  • Volume
    1,532,451
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.345
TimeVolumeCARA
09:32 ET218120.354999
09:33 ET3520.355
09:37 ET27000.3502
09:39 ET174900.3501
09:42 ET717050.33415
09:44 ET39890.3256
09:46 ET15000.342999
09:50 ET45800.3351
09:51 ET501000.3394
09:53 ET141050.3429
09:55 ET22910.345
09:57 ET3000.3429
10:00 ET1810.3411
10:02 ET90000.345
10:04 ET1000.3439
10:06 ET23000.3481
10:08 ET59450.3413
10:15 ET54440.34725
10:18 ET1250.3396
10:20 ET146010.34
10:22 ET6200.341187
10:24 ET1000.3422
10:26 ET1250.342555
10:29 ET115410.3421
10:31 ET87000.342
10:38 ET1000.349
10:40 ET1870.349
10:44 ET107000.345
10:51 ET45400.3466
10:54 ET81000.3466
10:56 ET134000.3547
10:58 ET266110.355
11:00 ET746260.3574
11:02 ET146250.3575
11:03 ET176730.3575
11:05 ET545080.363977
11:07 ET50090.364
11:09 ET1746550.3645
11:12 ET269530.358185
11:14 ET11420.364
11:16 ET6340.355801
11:18 ET69770.3619
11:20 ET254000.359899
11:21 ET155700.350601
11:23 ET101000.3549
11:25 ET107500.355
11:27 ET100000.3598
11:30 ET55000.3599
11:32 ET19160.3558
11:36 ET5000.3558
11:38 ET477440.3501
11:39 ET102000.3466
11:41 ET30560.349799
11:43 ET139360.345
11:45 ET1000.3498
11:52 ET1000.3499
11:54 ET1000.3499
11:56 ET8000.3499
11:57 ET7290.3444
11:59 ET99000.3487
12:01 ET125600.3499
12:06 ET1000.3496
12:08 ET23500.3446
12:10 ET8000.3445
12:17 ET103240.3495
12:26 ET48590.3444
12:30 ET11500.3445
12:35 ET22000.345
12:37 ET199580.3435
12:42 ET14050.3442
12:44 ET24150.342
12:48 ET2640.34345
12:50 ET2990.342001
12:51 ET1230.342001
12:53 ET21570.3448
12:55 ET56500.342
01:00 ET13420.34
01:04 ET73500.3448
01:06 ET21500.34
01:11 ET172520.3401
01:13 ET22520.3447
01:15 ET5500.3408
01:18 ET4830.3441
01:22 ET11570.3441
01:24 ET5000.3441
01:27 ET32600.3441
01:29 ET219540.344
01:31 ET2620.344
01:33 ET8340.34
01:36 ET54500.3373
01:38 ET19100.3314
01:44 ET2010.3314
01:47 ET17390.3315
01:51 ET8950.3315
01:56 ET10520.3315
02:02 ET23910.3314
02:03 ET1000.3314
02:05 ET2900.3314
02:07 ET896860.33
02:09 ET1000.343
02:20 ET5800.332239
02:21 ET12250.343
02:23 ET1100.33825
02:25 ET10000.33835
02:27 ET4500.3439
02:32 ET23090.332801
02:34 ET12500.343899
02:36 ET23720.3329
02:39 ET10000.3384
02:57 ET1800.3438
03:06 ET3000.3393
03:10 ET1000.3349
03:21 ET8920.3436
03:28 ET1950.3349
03:37 ET1000.3436
03:39 ET10000.3381
03:42 ET243560.3351
03:44 ET12330.3395
03:46 ET311000.335
03:48 ET101500.335
03:50 ET319770.333
03:51 ET11500.330101
03:53 ET3000.330101
03:55 ET95610.336
03:57 ET13000.336
04:00 ET1024020.3399
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCARA
Cara Therapeutics Inc
18.6M
-0.2x
---
United StatesTSBX
Turnstone Biologics Corp
12.3M
-0.2x
---
United StatesSQZB
SQZ Biotechnologies Co
678.3K
0.0x
---
United StatesVDRM
Viaderma Inc
9.9M
0.0x
---
United StatesICCC
ImmuCell Corp
27.7M
-6.8x
---
United StatesHOOK
HOOKIPA Pharma Inc
45.3M
-0.7x
---
As of 2024-11-10

Company Information

Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Contact Information

Headquarters
400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901
Phone
203-406-3700
Fax
203-567-1510

Executives

Independent Chairman of the Board
Martin Vogelbaum
President, Chief Executive Officer, Director
Christopher Posner
Chief Financial Officer
Ryan Maynard
Chief Compliance Officer, General Counsel, Secretary
Scott Terrillion
Director
Helen Boudreau

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$18.6M
Revenue (TTM)
$11.0M
Shares Outstanding
54.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.67
EPS
$-2.04
Book Value
$1.05
P/E Ratio
-0.2x
Price/Sales (TTM)
1.7
Price/Cash Flow (TTM)
---
Operating Margin
-1,000.06%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.